Hepatitis is a world’s public health problem and Indonesia is not an exception. Indonesia has high incidence of Hepatitis B that makes it the second highest country with Hepatitis B incidence after Myanmar. Hepatitis B can be transmitted through blood transfusions, contaminated needles, razors, tattoos, and organ transplants. This disease can be transmitted from mother to baby during childbirth or while still in the womb. In collaboration with PT. Biofarma Tbk, a state-owned company (BUMN) which produces test vaccines located in Bandung, Indonesia, Medical Faculty of Diponegoro University (MFDU) conducts this research which have been granted permission from the Health Research Ethics Commission of FK UNDIP and BPOM.
Tittle of the research is Protectivity and Safety Following Recombinant Hepatitis B Vaccine with Different Source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) Vaccine in Indonesia Population
The research held in August 2019 until August 2020
Principal Investigator: dr. Yetty Movieta Nency SpA(K)
Sub Investigator:
- Farid Agung Rahmadi, M.Si.Med., Sp.A
- Nur Farhanah, M.Si.Med., Sp.PD-KPTI
- Rebriarina Hapsari, M.Sc. Sp.MK(K).
- Mulyono, Sp.A
- Dimas Tri Anantyo, Sp.A.
